We need your help fixing hair loss for good
HairDAO is an open-source R&D network where patients and researchers collaborate to develop revolutionary new treatments for hair loss. Log your treatment experiences, contribute to cutting-edge research, and earn HAIR as a reward.
8 in 10 men
and half of all women will experience hair loss in their lifetimes.
66% of men
will experience noticeable hair loss before the age of 35.
0 new treatments
have been brought to market since Finasteride in 1997.
0.004%
of all early stage R&D funding goes to hair loss research. That's only $5.4 million a year!
We think patients deserve better
HairDAO is an open-source R&D network where patients and researchers collaborate to develop revolutionary new treatments for hair loss. We believe in the power of a community to tackle big, hairy challenges and make hair loss a thing of the past.
AS SEEN IN
Our research is developed, governed and owned by our community
In our community, the power to decide which research projects receive funding lies with the community members themselves. Both academics and informed community members, who have delved deeply into the relevant literature, are encouraged to propose projects. The ability to vote on which projects should be supported is granted through holding the HAIR token. This democratic approach ensures that a wide range of perspectives are considered in the decision-making process, fostering a diverse and innovative research environment.
TRH
Thyrotropin-releasing Hormone, a neurohormone known for its role in the hypothalmic-pituitary-thyroid axis, has exhibited promising regrowth effects on human hair follicles ex vivo.
PATENT FILED
T3
Liothyronine, the most potent of the four thyroid hormones, has shown measurable regrowth effects on human scalp skin and human hair follicles ex vivo.
PATENT FILED
T4
Levothyroxine, the inactive form of Liothyronine, has also exhibited measurable regrowth effects on human scalp skin and human hair follicles ex vivo.
PATENT FILED
Dutasteride
Dutasteride, the most efficacious hair loss treatment today, comes with a suite of harmful side effects. We seek to eliminate those in our delivery vehicle research.
FUNDED
Twist-1 and 2i
Twist-1 inhibition remains our top protein target. Our study tests 11 Twist inhibitors on human dermal papilla cells and human hair follices in vitro.
FUNDED
YAP-1i
YAP-1 inhibition offers the promise for scarless hair transplants. We’ve partnered with Dr. Taleb Barghouthi and Dr. Blake Bloxham to discover more.
FUNDED
Naltrexone
Naltrexone, an FDA-approved drug for alcohol and opioid use disorder, has exhibited measurable hair growth effects in human hair follicles ex vivo.
PATENT FILED
Olanzapine
Olanzapine, an FDA-approved drug for schizophrenia and bipolar disorder, has exhibited measurable hair growth effects in human hair follicles ex vivo.
PATENT FILED
Doxycycline
Doxycycline, an FDA-approved antibiotic for various types of infections, has exhibited measurable hair growth effects in human hair follicles ex vivo.
PATENT FILED
Farnesol
Farnesol, a cosmetic antibacterial and antifungal, has exhibited measurable hair growth effects in human hair follicles ex vivo.
PATENT FILEDMEET OUR PARTNERS
Ready to dive in?
Anonymously log your treatment progress, help us advance hair loss research, and earn
governance rights in the DAO.
